DEVA HOLDING AS
GenericsDEVA HOLDING AS is a generic drug manufacturer focused on Infectious Disease, Respiratory, Gastroenterology.
DEVA HOLDING AS's Key Drugs
DEVA HOLDING AS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
DEVA HOLDING AS's Recent FDA Approvals
New NDA/BLA approvals for DEVA HOLDING AS over the last two years — novel drugs only, excluding generics and label supplements.
DEVA HOLDING AS's Therapeutic Areas
DEVA HOLDING AS's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DEVA HOLDING AS's Top Competitors
DEVA HOLDING AS's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DEVA HOLDING AS Pipeline Snapshot
DEVA HOLDING AS has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2017-03-06
- Latest
- 2026-05-01
- Applications
- 16